Linda Malek

Partner & CHS Managing Director

Overview

Linda Malek is a partner in Crowell & Moring’s Health Care and Privacy and Cybersecurity groups in New York, and a managing director at Crowell Health Solutions. She advises a broad array of health care and life sciences clients on compliance with federal, state, and international law governing clinical research, data privacy, cybersecurity, and fraud and abuse. Her clients include national hospital systems and academic medical centers; genetic, health technology, and biotechnology companies; pharmaceutical companies; medical device companies; financial institutions involved in health care services; research foundations; and international scientific organizations.

In the health care context, Linda is particularly focused on regulatory compliance issues related to clinical research and clinical trials. She creates and implements comprehensive policies governing the conduct of research involving human subjects and advises clients on human subject research compliance issues. Linda also counsels on legal issues related to conducting secondary research on existing data repositories and tissue banks, including on data privacy and informed consent issues related to the ability to conduct future research. She has experience advising clients on a wide variety of research areas, including biologics, pharmacogenomics, translational research, secondary research, tissue banking, and data repositories. Linda also counsels digital health and biotech companies developing AI tools in the complex and evolving federal and state regulatory landscape, balancing the priorities of oversight authorities with issues related to data privacy and security as well as business goals. She also advises clients on general health care matters related to fraud and abuse, including issues under the Stark laws and federal and state anti-kickback statutes. Her work includes structuring complex transactions in compliance with such laws, assisting in the creation of internal compliance programs, and advising on issues related to the False Claims Act.

Linda’s privacy and cybersecurity practice involves advising clients in both the private and public sectors regarding the complex interaction of, and compliance with, various state, federal, and international data privacy laws, including the Health Insurance Portability and Accountability Act, the Gramm-Leach-Bliley Act, the Children's Online Privacy Protection Act, the Health Information Technology for Economic and Clinical Health Act, the Family Educational Rights and Privacy Act, federal law regarding the protection of human research subjects, the European Union’s General Data Privacy Regulations, and the FTC and state enforcement activities. She counsels clients on both transactional and regulatory issues across industries on issues related to the use of personal data.

Linda advises on issues relevant to the collection, storage, protection, and authorized use of personally identifiable information (PII). Her work includes performing compliance audits, structuring transactions, and drafting agreements, and, when needed, assisting clients in conducting internal investigations.

Linda began her legal career in government and served as an attorney for the Office of the Corporation Counsel, Division of Legal Counsel, where she focused on health policy issues and was named Outstanding Assistant Corporation Counsel by the Association of the Bar of the City of New York.

Linda is a respected leader in the field, recognized by top legal publications. She was recognized in The Best Lawyers in America® for 2022 through 2024, included in the list of Notable Women in Law by Crain’s New York Business in 2020, and honored by New York Metro Super Lawyers in seven consecutive editions. In 2024, Linda was listed in Chambers USA as up and coming in health care.

Career & Education

    • New York
      Office of the Corporation Counsel, Division of Legal Counsel, 1993–1999
    • New York
      Office of the Corporation Counsel, Division of Legal Counsel, 1993–1999
    • Walla Walla University, B.A., cum laude
    • University of Virginia School of Law, J.D.,

      Editorial Board Member, Journal of Law and Politics


      Recipient, Mary Claiborne and Roy H. Ritter Award, The University of Virginia School of Law
    • Walla Walla University, B.A., cum laude
    • University of Virginia School of Law, J.D.,

      Editorial Board Member, Journal of Law and Politics


      Recipient, Mary Claiborne and Roy H. Ritter Award, The University of Virginia School of Law
    • New York
    • New York
    • Board Member, NYBIO
    • Trustee, Lucy B. Moses Foundation
    • Former member of Educational Advisory Board, International Association of Privacy Professionals
    • Founding Board, National Board of Health Lawyers, a division of NBTA (National Board of Trial Advocacy)
    • American Bar Association, Health Reform Task Force
    • American Health Lawyers Association
    • Board Member, NYBIO
    • Trustee, Lucy B. Moses Foundation
    • Former member of Educational Advisory Board, International Association of Privacy Professionals
    • Founding Board, National Board of Health Lawyers, a division of NBTA (National Board of Trial Advocacy)
    • American Bar Association, Health Reform Task Force
    • American Health Lawyers Association
    • French
    • French

Linda's Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

Recognition

  • Chambers USA: Healthcare, New York, 2024–2025
  • Best Lawyers in America: 2022–2024, 2026
  • Super Lawyers: 2013–2024

Linda's Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

Linda's Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...